Benchmark Genetics appointed David Farcas Guendelman as director of Benchmark Genetics in Chile. The incorporation follows the arrival of the company in Chile three years ago where the company has been developing a strain challenged and improved against local diseases and sanitary conditions with good performance and high predictability and homogeneity.
“Benchmark Genetics has been doing an excellent job in the productive and technical aspect, with results that are being recognized in the Chilean market with seven salmon farmers who have trusted in us. I am confident that we will be able to capitalize on what has been done, understanding that the results of our clients are also ours,” said Farcas.
Farcas expertise includes fish health, after years of leading Centrovet and the development of safety products, vaccines and disease control for salmon. He also chairs the Committee of Scientific Advisors of the Ministry of Science and Technology that led the evaluation of COVID-19 vaccines and the coordination of phase III tests of these vaccines in Chile.
“We are happy to have David join the Benchmark Genetics team in our country; experience and knowledge of the industry will be a tremendous contribution. His participation as director will consolidate what we have built over the years, reaching different clients with eggs of the highest quality and unique biosafety standards, yielding very good performance in freshwater and the sea. We have consolidated a technical team with great experience and commitment, improving our production facilities and advancing in the implementation of the highest certification standards,” added Pablo Mazo, general manager of Benchmark Genetics Chile.